Transforming Ideas into Impact

Thomas E. D’Ambra, Ph.D., co-founds Albany Molecular Research, Inc.

Albany Molecular Research, Inc. becomes a publicly traded company on the NASDAQ.

Albany Molecular Research, Inc., changes its name to AMRI to reflect our evolution into a global contract services and R&D organization.

Acquisition of Cedarburg Pharmaceuticals, Inc. The Grafton, Wisc., company develops and manufactures complex APIs including controlled substances and steroids, allowing us to offer a greater breadth of resources, including expanded scale-up capabilities and large-scale manufacturing at lower costs.

Acquisition of Oso BioPharmaceuticals Manufacturing, a premier contract manufacturer of complex injectable drug products and a former portfolio company of Altaris Capital Partners, LLC. The acquisition complements our custom and complex drug product development and manufacturing offerings, making AMRI a single source for addressing sterile fill/finish needs from Phase I development through large-scale commercial supply.

Acquisition of two Aptuit businesses — SSCI, a West Lafayette, Ind., company, and Aptuit’s Glasgow, U.K., facility. These acquisitions strengthen key areas. SSCI provides expert material science knowledge and technology that expand AMRI’s analytical testing capabilities, and the Glasgow operation includes sterile injectable drug product formulation and clinical manufacturing that extend our parenteral offerings, particularly in Europe.

Acquisition of Gadea Pharmaceutical Group, a privately held company in Valladolid, Spain. The acquisition bolsters AMRI’s development and manufacturing services in both branded and generic pharmaceuticals and expands our API portfolio — strengthening our capabilities in steroids and hormones and sterile drug product offerings in ophthalmic and parenteral suspension dosage forms, prefilled syringes and lyophilization.

Acquisition of Whitehouse Laboratories, a Lebanon, N.J.-based provider of testing services including materials and excipients, container qualification and container closure integrity testing, analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability and storage programs. The acquisition extends AMRI’s state-of-the-art solutions to meet increasingly complex analytical and testing needs.

Launch of integrated drug discovery center in Buffalo, N.Y., in partnership with New York State as a founding member of the Buffalo Medical Innovation and Commercialization Hub. The center provides a single site for biology, high-throughput screening, in vitro pharmacology and medicinal chemistry for increased collaboration and speed in decision making to accelerate innovation.

Acquisition of Prime European Therapeuticals S.p.A., also known as Euticals, a privately held company headquartered in Lodi, Italy. Euticals’ custom synthesis and API manufacturing capabilities broadens AMRI’s custom synthesis offerings in key European markets and positions us as one of the largest independent developers and suppliers of APIs to the pharma industry.

AMRI relaunches as Curia. The new name reinforces the company’s strategic positioning as an end-to-end global CDMO, enabling biopharmaceutical customers to advance important new products that improve lives. Along with the name change, the company introduces a new brand identity.

Acquisition of Integrity Bio, Inc, a formulation and fill-finish organization headquartered in Camarillo, C.A. enhancing Curia’s drug product formulation development capabilities and expands its fill-finish network, which also includes Curia’s three center-of-excellence facilities.

Expansion of commercial manufacturing capacity at our Rensselaer, New York facility. The increased capability to flexibly manufacture complex Active Pharmaceutical Ingredients (APIs) strengthens Curia’s ability to partner with customers, meeting small-scale to large-volume requirements with reliable delivery.

Acquisition of LakePharma Inc., a biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts and Texas. With this acquisition, Curia offers deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.